Compare Amphastar Pharmaceuticals Inc (AMPH) vs KE Holdings Inc (BEKE) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

BEKE trades at $15.57, up 2.1% today, with a bearish technical signal despite recent earnings beat. The company reported strong Q1 2026 results with EPS of $0.20 beating expectations of $0.14, driven by improved profitability despite lower revenue. Analyst consensus remains overwhelmingly bullish with 91.7% buy ratings, while technical indicators show oversold conditions suggesting potential reversal.

The outlook appears constructive given improving profitability and positive analyst sentiment, though risks include China's property market volatility and recent cash flow challenges. The stock's current valuation at P/E 35.6x reflects growth expectations, with potential upside if operational improvements continue.